Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients
- 1 November 1993
- journal article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 66 (791) , 1009-1015
- https://doi.org/10.1259/0007-1285-66-791-1009
Abstract
We have analysed the medical records and diagnostic imaging of 76 patients presenting to this hospital for treatment of uterine sarcoma between 1970 and 1990. Patients were divided into those presenting before 1980 (n = 22) and after 1980 (n = 54), when sectional imaging (ultrasound, CT scanning) and more modern radiotherapy and chemotherapy were introduced. No survival difference was observed between these two groups. In those patients presenting after 1980, the median age was 54 years (range 18-80), and median survival 22 months from initial diagnosis. Factors associated with a significantly improved survival included low grade (although not histological type) of initial tumour (p = 0.001) and Stage I disease at presentation (p = 0.006). In 17 patients receiving pelvic radiotherapy following initial surgery, both the time to relapse (p = 0.005) and overall survival (p = 0.045) were increased. Adjuvant chemotherapy in 19 patients did not improve outcome. Most diagnoses of relapse were established clinically; they occurred most frequently in the pelvis, followed by lung and abdomen. Pulmonary relapse was accompanied by spontaneous pneumothorax in two cases. Bone and brain metastases were uncommon (< 10%). Following diagnosis of relapse, the median survival was 9 months, with the outcome significantly worse if multiple metastatic sites were involved (p < 0.001). No survival benefit was demonstrated from either local radiotherapy or combination chemotherapy once relapse had occurred. Prognostic factors and current policies for the diagnosis and management of uterine sarcomas are discussed.Keywords
This publication has 16 references indexed in Scilit:
- Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcomaBJOG: An International Journal of Obstetrics and Gynaecology, 1992
- Retrospective analysis of 318 cases of uterine sarcomaEuropean Journal of Cancer and Clinical Oncology, 1991
- Prospective Trial of Cisplatin, Adriamycin, and Dacarbazine in Metastatic Mixed Mesodermal Sarcomas of the Uterus and OvaryAmerican Journal of Clinical Oncology, 1991
- Primary Uterine Endometrial Stromal NeoplasmsThe American Journal of Surgical Pathology, 1990
- Endometrial stromal sarcomasGynecologic Oncology, 1990
- Treatment of endometrial stromal tumorsGynecologic Oncology, 1990
- Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomasJournal of Surgical Oncology, 1988
- Uterine sarcomas: Prognostic factors and treatment modalities—Study on 209 patientsGynecologic Oncology, 1986
- Uterine sarcomas: A clinicopathologic study, 1965–1981Gynecologic Oncology, 1984
- Adjuvant chemotherapy in early uterine sarcomaGynecologic Oncology, 1983